Neuro-oncology: clinical and molecular predictive factors

The Lancet Neurology

Volumn 8, Issue 1, 2009, Pages 17-19

  Vecht, Charles J ^a  

^a Medical Center the Hague   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; CD133 ANTIGEN; FLUORESCENT DYE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DROWSINESS; GLIOBLASTOMA; HOX GENE; HUMAN; NAUSEA; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; VOMITING;

EID: 57149116743     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70278-3     Document Type: Note

References (10)

1. Stupp R., Mason W.P., van den Bent M.J., et al., European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
2. Murat A., Migliavacca E., Gorlia T., et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26 (2008) 3015-3024
3. Gorlia T., van den Bent M.J., Hegi M.E., et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981. Lancet Oncol 9 (2008) 29-38
4. Stummer W., Reulen H.J., Meinel T., et al., for the ALA-Glioma Study Group. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62 (2008) 564-576
5. The Oxford Centre for Evidence-based Medicine. http://www.cebm.net/index.aspx?0=1025 (accessed November 20, 2008).
6. Sanai N., Mirzadeh Z., and Berger M.S. Functional outcome after language mapping for glioma resection. N Engl J Med 358 (2008) 18-27
7. Brandes A.A., Franceschi E., Tosoni A., et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26 (2008) 2192-2197
8. Law M., Young R.J., Babb J.S., et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247 (2008) 490-498
9. Taphoorn M.J., van den Bent M.J., Mauer M.E., et al., for the European Organisation for Research and Treatment of Cancer. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol 25 (2007) 5723-5730
10. Arnold S.D., Forman L.M., Brigidi B.D., et al. Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors. Neuro Oncol 10 (2008) 171-181